“Commonly known as the stomach flu, norovirus has been around forever, and has become the leading cause of gastroenteritis or ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...

In September 2024, the European Commission (EC) granted marketing authorization for an updated formulation of Moderna's COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1, for ...

Moderna’s vaccine “could be able to cover upwards of 70 or 80% of the norovirus outbreaks that might occur in a given year. And with our mRNA technology, we would be able to update the vaccine ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

Kennedy Jr., a vocal vaccine skeptic ... they can be developed and updated more quickly. HHS said its award to Moderna was, in part, to “enhance mRNA platform capabilities.” ...

Moderna continues to innovate in this space, with updated boosters as well as differentiated programs like next-generation vaccine mRNA-1283 (to launch in 2025), which is more stable at ...

Anyone who thought (as I did) that the worst was over for Moderna's COVID-19 vaccine sales will be especially bothered by the company's update. But while Moderna's near-term prospects don't look ...

Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.

In September 2024, the European Commission (EC) granted marketing authorization for an updated formulation of Moderna's COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.